BIOXCEL THERAPEUTICS

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at ThinkEquity Conference

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

21 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

24 Apr 2024 10:30:24 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

15 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire